Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis mystery: could toxin clearance explain survival boost?

NCT ID NCT06515899

Knowledge-focused Sponsor: East and North Hertfordshire NHS Trust Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study looks at why a specific type of dialysis called haemodiafiltration (HDF) improves survival when higher fluid volumes are used. Researchers think it may be because larger waste molecules are removed more effectively and blood pressure stays more stable. They will measure these factors in 342 adults with end-stage kidney disease who are already on HDF. The goal is to see if prescribing dialysis based on toxin clearance rather than volume could help more patients benefit.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If the link is confirmed, doctors might prescribe dialysis based on toxin clearance rather than volume, making treatment more effective for more patients.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The results may not change practice if other factors are at play.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

342 people

The number who actually took part.

Started

Jan 2024

Finished

Jul 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

End stage renal failure patient having renal replacement therapy in the form of Haemodiafiltration.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or above. * Ability to give informed consent. * End stage renal failure treated by dialysis for at least 3 months. * Established on hemodiafiltration for \>4 weeks. * Prognosis more than 6 months as assessed by PI Exclusion Criteria: * Age less than 18 years. * Inability to give informed consent. * Prognosis less than 6 months as assessed by PI

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End stage renal disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End stage renal disease

Contacts and locations

Locations

  • East and North Hertfordshire NHS Trust

    Stevenage, Hertfordshire, SG1 4AB, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.